Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4.
about
Hepatitis C and insulin action: An intimate relationshipHepatitis C genotype 4: The past, present, and futureCurrent status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study.Meta-analysis: influence of host and viral factors in patients with chronic hepatitis C genotype 4 treated with pegylated interferon and ribavirin.The impact of interleukin 28b gene polymorphism on the virological response to combined pegylated interferon and ribavirin therapy in chronic HCV genotype 4 infected egyptian patients using data mining analysisInsulin resistance and chronic liver disease.Chronic hepatitis c genotype-4 infection: role of insulin resistance in hepatocellular carcinoma.Impact of insulin resistance on HCV treatment response and impact of HCV treatment on insulin sensitivity using direct measurements of insulin actionSustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis.SASLT practice guidelines: management of hepatitis C virus infection.Novel non-invasive biological predictive index for liver fibrosis in hepatitis C virus genotype 4 patientsDiabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review.The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients.Current understanding of insulin resistance in hepatitis C.Metabolic alterations and chronic hepatitis C: treatment strategies.How to optimize HCV therapy in genotype 4 patients.Optimal therapy in genotype 4 chronic hepatitis C: finally cured?Concurrent Obesity, Diabetes, and Steatosis Increase Risk of Advanced Fibrosis Among HCV Patients: A Systematic Review.Insulin Resistance is Associated With Significant Liver Fibrosis in Chronic Hepatitis C Patients: A Systemic Review and Meta-Analysis.Improvement of glycemic state among responders to Sofosbuvir-based treatment regimens: Single center experience.Polymorphisms at IL28B gene as predictors of viral relapse in genotype 4 Egyptian hepatitis C patients.Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: does ethnicity matter?Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment.IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4.IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.Meta-analysis: insulin resistance and sustained virological response in hepatitis C.Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients.Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients.Impact of IL28B gene polymorphisms rs8099917 and rs12980275 on response to pegylated interferon-α/ribavirin therapy in chronic hepatitis C genotype 4 patients.
P2860
Q26775000-775B0D48-FEA9-4F15-BAF0-D28616139591Q26775815-C4043093-DEEF-4FE8-A4C5-56DF8994BE18Q26828972-70817EBD-6332-44F0-BA04-68FFC533FB67Q33918559-2DB80AAA-2C90-4E6F-9443-25DB3BD49F72Q34270336-2EE2CEF1-955B-4B9E-AE92-0AE4B3F94349Q34996891-55D868FE-223C-4442-8970-6710BDADFCE0Q35073012-90C9A5C1-79B5-47C0-89AF-A73D38DDE360Q35555547-3A33BBA0-A930-42E7-991D-F3B8E45C04B7Q35898216-874D213B-65D5-45E6-BCE8-D8647A790E53Q36140466-5AF1FFE4-D2B5-4DB3-B732-35576A538577Q37019765-CB320D61-8B39-4A2C-ABFF-BC67B5AA120CQ37421485-B41F1B57-16A1-45A5-9BFF-0A020D795E9DQ37685491-8FAA353D-33B1-4884-B6D7-C74C45211A3DQ37711317-A4302530-F7F3-4AF0-A7F2-36D59C03A141Q37903853-63926963-3BDB-4368-94C9-399078EE3830Q37924816-B05E13FE-43DC-42F8-AAFE-B6A226525A28Q38071388-2BBAAF94-EB49-4F77-B787-FA8C4C386907Q38295814-8B6E3BDD-0ED8-40FA-B2E7-8DF23A6727D7Q38542209-6AB1AA06-F115-48B1-898A-35322D557605Q38572687-999746CF-AE3C-4EF1-8F29-D8DDF74F973BQ38688630-CEEA5A97-C6EA-42DF-ABD7-3698B112639FQ38995225-A4E6EAD6-1F7A-4E27-93D4-BC67FD937F84Q39337505-A38697C5-77FF-4A20-9029-3E14612A356DQ41172281-451A990F-2409-4B13-B335-E00165892217Q42987167-8BF00983-F8A0-4EEC-8D1A-98189F9F6D40Q43035545-89FE60EB-CE72-437F-99C0-03140273B731Q43037279-4A7C3A9E-B0E6-4DD0-B03F-D4BD935F3B28Q43740937-3D62072B-F0A5-4683-A382-31121CF243B9Q44189369-7E07C2F4-C525-44DD-8FDA-970F04124954Q46913441-29012279-B3FE-490A-9434-7FA194CA5BEB
P2860
Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Insulin resistance and geograp ...... rferon and ribavirin in HCV-4.
@en
Insulin resistance and geograp ...... rferon and ribavirin in HCV-4.
@nl
type
label
Insulin resistance and geograp ...... rferon and ribavirin in HCV-4.
@en
Insulin resistance and geograp ...... rferon and ribavirin in HCV-4.
@nl
prefLabel
Insulin resistance and geograp ...... rferon and ribavirin in HCV-4.
@en
Insulin resistance and geograp ...... rferon and ribavirin in HCV-4.
@nl
P2093
P356
P1433
P1476
Insulin resistance and geograp ...... rferon and ribavirin in HCV-4.
@en
P2093
A-C Cardoso
M Martinot-Peignoux
M-H Nicolas-Chanoine
M-P Ripault
P Marcellin
P304
P356
10.1136/GUT.2009.185074
P407
P577
2009-08-10T00:00:00Z